Matrix metalloproteinase (MMP)-7 in salivary gland cancer

Acta Oncologica

Volumn 49, Issue 1, 2010, Pages 85-90

  Luukkaa, Heikki ^a   Klemi, Pekka ^b   Hirsimäki, Pirkko ^a   Vahlberg, Tero ^b   Kivisaari, Atte ^b,c   Kähäri, Veli Matti ^b,c   Grénman, Reidar ^a,b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MATRILYSIN;

ACINAR CELL CARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; ENZYME ASSAY; FEMALE; FINLAND; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SALIVARY GLAND CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ACINAR CELL; CARCINOMA, DUCTAL; CARCINOMA, MUCOEPIDERMOID; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SALIVARY GLAND NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 76649088007     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/02841860903287197     Document Type: Article

References (26)

1. Shah JP, Patel SG. Head and neck surgery and oncology. 3rd ed. Edinburgh: Mosby; 2003.
2. Östman J, Anneroth G, Gustafsson H, Tavelin B. Malignant salivary gland tumours in Sweden 1960-1989-an epidemiological study. Oral Oncol 1997;33:169-76.
3. Finnish Cancer Registry. October 10th 2008. Available from: URL: http://www.cancerregistry.fi/eng/.
4. Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, et al. Salivary gland cancer in Finland 1991-96: An evaluation of 237 cases. Acta Otolaryngol 2005;125:207-14.
5. Chen W, Zhang HL, Shao XJ, Jiang YG, Zhao XG, Gao X, et al. Gene expression profi le of salivary adenoid cystic carcinoma associated with perineural invasion. Tohoku J Exp Med 2007;212:319-34.
6. De S, Fenton JE, Jones AS. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease. J Laryngol Otol 2005;119:436-42.
7. Ala-aho R, Kähäri VM. Collagenases in cancer. Biochimie 2005;87:273-86.
8. Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5:203-20.
9. Saarialho-Kere UK, Crouch EC, Parks WC. Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 1995;105:190-6.
10. Johansson N, Kähäri VM. Matrix metalloproteinases in squamous cell carcinoma. Histol Histopathol 2000;15:225-37.
11. Wilson CL, Ouellette AJ, Satchell DP, Ayabe T, Lopez-Boado YS, Stratman JL, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999;286(5437):113-7.
12. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: Structure, function, and biochemistry. Circ Res 2003;92:827-39.
13. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci USA 2000;97:2202-7.
14. Luukkaa H, Klemi P, Hirsimaki P, Vahlberg T, Kivisaari A, Kähäri VM, et al. Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer. Acta Otolaryngol 2008;128:482-90.
15. Luukkaa H, Klemi P, Leivo I, Vahlberg T, Grenman R. Prognostic signifi cance of Ki-67 and p53 as tumor markers in salivary gland malignancies in Finland: An evaluation of 212 cases. Acta Oncol 2006;45:669-75.
16. Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001;19:1118-27.
17. Yamashita K, Mori M, Shiraishi T, Shibuta K, Sugimachi K. Clinical signifi cance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6:1169-74.
18. Yamamoto H, Itoh F, Adachi Y, Fukushima H, Itoh H, Sasaki S, et al. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma. Jpn J Clin Oncol 1999; 29:58-62.
19. Yamashita K, Azumano I, Mai M, Okada Y. Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer 1998;79:187-94.
20. Ito Y, Yoshida H, Kakudo K, Nakamura Y, Kuma K, Miyauchi A. Inverse relationships between the expression of MMP-7 and MMP-11 and predictors of poor prognosis of papillary thyroid carcinoma. Pathology 2006;38:421-5.
21. Lopez-Otin C, Matrisian LM. Emerging roles of proteases in tumour suppression. Nat Rev Cancer 2007;7:800-8.
22. Kivisaari AK, Kallajoki M, Mirtti T, McGrath JA, Bauer JW, Weber F, et al. Transformation-specifi c matrix metalloproteinases (MMP)-7 and MMP-13 are expressed by tumour cells in epidermolysis bullosa-associated squamous cell carcinomas. Br J Dermatol 2008;158:778-85.
23. Lynch CC, Vargo-Gogola T, Martin MD, Fingleton B, Crawford HC, Matrisian LM. Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor. Cancer Res 2007;67:6760-7.
24. Martin MD, Matrisian LM. The other side of MMPs: Protective roles in tumor progression. Cancer Metastasis Rev 2007;26:717-24.
25. Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM. Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia 2001;3:459-68.
26. Vargo-Gogola T, Crawford HC, Fingleton B, Matrisian LM. Identifi cation of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch Biochem Biophys 2002;408:155-61.